Skip to main content
SpringerLink
Log in

Venöse Thromboembolien, Thrombophilie und Thromboseprophylaxe in Gynäkologie und Geburtshilfe

Teil II: Medikamentöse Thromboembolie-Prophylaxe

  • Chapter
Book cover Weiterbildung Gynäkologie und Geburtshilfe

  • 1868 Accesses

Zussamenfassung

Venöse Thromboembolien (VTE) gehen mit hoher Morbidität und Mortalität einher. Wirksame Maßnahmen zur sicheren VTE-Prophylaxe stellen deshalb weiterhin eine Herausforderung in der täglichen klinischen Praxis dar. Dies trifft vor allem auf schwangere Frauen und Patientinnen mit gynäkologischen Malignomen zu. Niedermolekulare Heparine sind nach wie vor Mittel der Wahl zur medikamentösen VTE-Prophylaxe perioperativ, bei Risikoschwangerschaft und in der Postpartalphase. Allerdings können diese Substanzen Blutungen oder eine heparininduzierte Thrombozytopenie (Typ II) auslösen. Auf der Grundlage aktualisierter Leitlinien bietet dieser Artikel eine Übersicht zum Stand der medikamentösen Thromboembolie-Prophylaxe und erörtert Probleme und offene Fragen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 34.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 44.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bates SM, Greer IA, Middeldorp S et al (2012) VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e69–1 S-e736S (PubMed PMID: 22315276. Pubmed Central PMCID: 3278054)

    Google Scholar 

  2. Lo GK, Juhl D, Warkentin TE et al (2006) Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Hae- most 4(4):759-765 (PubMed PMID: 16634744)

    Google Scholar 

  3. Crowther MA, Cook DJ, Albert M et al (2010) The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. J Crit Care 25(2):287-293 (PubMed PMID: 20149589)

    Google Scholar 

  4. Gerhardt A, Scharf RE, Zotz RB (2009) Successful use of danaparoid in two pregnant women with heart valve prosthesis and heparin-induced thrombocytopenia Type II (HIT). Clin AppI Thromb Hemost 15(4):461-464 (PubMed PMID: 18840630)

    Google Scholar 

  5. Gerhardt A, Zotz RB, Stockschlaeder M, Scharf RE (2007) Fondaparinux is an effective alternative anticoagulant in pregnant women with high risk of venous thromboembolism and intolerance to low-molecular-weight heparins and heparinoids. Thromb Haemost 97(3)496-497 (PubMed PMID: 17334521)

    Google Scholar 

  6. Seidel HKH, Buchbinder S, Hoffmann T, Scharf RE (2014) Monitoring of argatroban and hirudin: what is the input of laboratory values in, real life'? zur Veröffentlichung eingereicht

    Google Scholar 

  7. Greinacher A, Seileng K (2010) Thrombocytopenia in the intensive care unit patient. Hematology Am Soc Hematol Educ Program 2010:135-143 (PubMed PMID: 21239783)

    Google Scholar 

  8. Schinzel H (2007) Einsatz von niedermolekularen Heparinen bei Niereninsuffizienz. Vascular Care 12(1):18–31

    Google Scholar 

  9. Hull RD, Pineo GF, Stein PD et al (2001) Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients follo-wing elective hip arthroplasty: a systematic review. Arch Intern Med 161 (16):1952-1960 (PubMed PMID: 11525697)

    Google Scholar 

  10. Clarke-Pearson DL, Abaid LN (2012) Prevention of venous thromboembolic events after gynecologic surgery. Obstet Gynecol 119(1 ):155-167 (PubMed PMID: 22183223)

    Google Scholar 

  11. Gould MK, Garcia DA, Wren SM et al (2012) Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e22–7S-e277S (PubMed PMID: 22315263. Pubmed Central PMCID: 3278061)

    Article  Google Scholar 

  12. Guyatt GH, Akl EA, Crowther M et al (2012) Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):7S-47S (PubMed PMID: 22315257. Pubmed Central PMCID: 3278060)

    Article  Google Scholar 

  13. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P (2009) Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Cochrane Database Syst Rev 1 :CD004318 (PubMed PMID: 19160234)

    Google Scholar 

  14. Peedicayil A, Weaver A, Li X et al (2011) Incidence and timing of venous thromboembolism after surgery for gynecological cancer. Gynecol Oncol 121 (1):64-69 (PubMed PMID: 21183211)

    Google Scholar 

  15. Blom JW, Vanderschoot JP, Oostindier MJ et al (2006) Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 4(3)529-535 (PubMed PMID: 16460435)

    Google Scholar 

  16. Andtbacka RH, Babiera G, Singletary SE et al (2006) Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways. Ann Surg 243(1 ):96- 101 (PubMed PMID: 16371742. Pubmed Central PMCID: 1449977)

    Google Scholar 

  17. Friis E, Horby J, Sorensen LT et al (2004) Thromboembolic prophylaxis as a risk factor for postoperative complications after breast cancer surgery. World J Surg 28(6)540-543 (PubMed PMID: 15366741)

    Google Scholar 

  18. Scharf RE (2011) Cancer, thromboembolia and antithrombotic therapy: is there an anticoagulant of choice? Dtsch Med Wochenschr 136(47):2403 (PubMed PMID: 22094968. Tumorkrankheit, Thromboembolien und antithrombotische Therapie: Gibt es ein Antikoagulans der Wahl?)

    Google Scholar 

  19. Kuderer NM, Khorana AA, Lyman GH, Francis CW (2007) A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 110(5):1149-1161 (PubMed PMID: 17634948)

    Google Scholar 

  20. Lyman GH, Khorana AA, Falanga A (2007) American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25(34)5490-5505 (PubMed PMID: 17968019)

    Google Scholar 

  21. Chan WS (2009) The, ART' of thrombosis: a review of arterial and venous thrombosis in assisted reproductive technology. Curr Opin Obstet Gynecol 21 (3):207-218 (PubMed PMID: 19276806)

    Google Scholar 

  22. Bates SM, Greer IA, Pabinger I et al (2008) Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133(6 Suppl):844S-886S (PubMed PMID: 18574280)

    Google Scholar 

  23. Zotz RB, Gerhardt A, Scharf RE (2006) Pregnancy-associated venous thromboembolic disease: prediction, prevention, and therapy. Ha- mostaseologie 26(1):63-71 (PubMed PMID: 16444326. Venose Thrombose in der Schwangerschaft. Pradiktion, Prävention und Therapie)

    Google Scholar 

  24. Zotz RB, Sucker C, Gerhardt A (2008) Thrombophilia in pregnancy: venous thromboembolism, fetal loss, preeclampsia, intrauterine growth restriction. Hamostaseologie 28(5):455- 464 (PubMed PMID: 19132175. Thrombophile Hamostasestörung in der Schwangerschaft:Thrombo- se, Abort, Praeklampsie, intrauterine Wachstumsretardierung)

    Google Scholar 

  25. Duley L, Henderson-Smart DJ, Meher S, King JF (2007) Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2:CD004659 (PubMed PMID: 17443552)

    Google Scholar 

  26. Bujold E, Roberge S, Lacasse Y et al (2010) Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 116(2 Pt 1 ):402-414 (PubMed PMID: 20664402)

    Google Scholar 

  27. Middeldorp S (2007) Thrombophilia and pregnancy complications: cause or association? J Thromb Haemost 5(Suppl 1):276-282 (PubMed PMID: 17635737)

    Google Scholar 

  28. Isermann B, Sood R, Pawlinski R et al (2003) The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med 9(3)531-337 (PubMed PMID: 12579195)

    Google Scholar 

  29. Pabinger I (2008) Thrombophilia and its impact on pregnancy. Hamostaseologie 28:130–134

    CAS  PubMed  Google Scholar 

  30. Rath W, Thaler JC (2013) Hereditäre Thrombophilien und Plazenta-medierte Schwangerschaftskomplikationen im II./III.Trimenon. Hamostaseologie 33:21–36

    Article  CAS  PubMed  Google Scholar 

  31. Kupferminc MJ, Rimon E, Many A et al (2011) Low molecular weight heparin treatment during subsequent pregnancies of women with inherited thrombophilia and previous severe pregnancy complications. J Matern Fetal Neonatal Med 24(8):1042- 1045 (PubMed PMID: 21231837)

    Article  CAS  PubMed  Google Scholar 

  32. Gris JC, Chauleur C, Molinari N et al (2011) Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial. Thromb Haemost 106(6):1053-1061 (PubMed PMID: 21946915)

    Google Scholar 

  33. Vries Jl de,PMG, Hague WM et al (2012) Low-molecular- weight heparin added to aspirin in the prevention of recurrent early-on- set pre-eclampsia in women with inheritable thrombophilia: the FRUIT- RCT. J Thromb Haemost 10(1):64-72 (PubMed PMID: 22118560)

    Google Scholar 

  34. Schaefer C, Hannemann D, Meister R et al (2006) Vitamin K antagonists and pregnancy outcome. A multicentre prospective study. Thromb Haemost 95(6):949-957 (PubMed PMID: 16732373)

    Google Scholar 

  35. Piper C, Hering D, Horstkotte D (2001) Prosthetic valve thrombosis: predispostion and diagnosis. Eur Heart J 3(Suppl Q):Q16–Q21

    Google Scholar 

  36. Gogarten W, Aken H van, Büttner J et al (2007) Rückenmarksnahe Regionalanästhesien und Thromboem- bolieprophylaxe/antithrombotische Medikation. 2. überarbeitete Empfehlung der Deutschen Gesellschaft für Anästhesiologie und Intensivmedizin. Anästh Intensivmed 485109- S124

    Google Scholar 

  37. Geerts WH, Bergqvist D, Pineo GF et al (2008) Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice gui-delines (8th Edition). Chest 133(6 Suppl):381 S-453S (PubMed PMID: 18574271)

    Google Scholar 

  38. Scharf RE (2011) Hemostatic disorders: clinical management based on molecular mechanisms. Fortschr Neurol Psychiat 79(3):171-185 (quiz 86-88) (PubMed PMID: 21394708. Storungen des Hamostasesystems: Molekulare Mechanismen als Grundlage von Diagnostik und Therapie)

    Google Scholar 

  39. Rosendaal FR, Reitsma PH (2009) Genetics of venous thrombosis. J Thromb Haemost 7(Suppl 1 ):301 - 304 (PubMed PMID: 19630821)

    Google Scholar 

  40. Sartori MT, Wiman B, Vettore S et al (1998) 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis. Thromb Haemost 80(6):956-960 (PubMed PMID: 9869167)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Hämostaseologie, Hämotherapie und Transfusionsmedizin & Hemophilia Comprehensive Care Center, Universitätsklinikum, Heinrich-Heine-Universität, Düsseldorf

    R.E. Scharf

  2. Klinik für Gynäkologie und Gynäkologische Onkologie & Klinik für Geburtshilfe und Perinatologie, Universitäts-Frauenklinik, Universitätsklinikum, Albert-Ludwigs-Universität, Freiburg

    M.A. Pestka

Authors
  1. R.E. Scharf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M.A. Pestka
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinikum Kassel, Frauenklinik, Kassel, Deutschland

    Thomas Dimpfl

  2. Universitätsklinik Ulm, Frauenklinik, Ulm, Deutschland

    Wolfgang Janni

  3. Landshut, Deutschland

    Rolf Kreienberg

  4. Klinik für Gynäkologie und Geburtshilfe, Universitätsklinik Kiel, Kiel, Deutschland

    Nicolai Maass

  5. Klinik für Frauenheilkunde und Geburtshilfe, Caritas-Krankenhaus St. Josef, Regensburg, Deutschland

    Olaf Ortmann

  6. Frauenklinik, Universitätsklinik Heidelberg, Heidelberg, Deutschland

    Thomas Strowitzki

  7. Klinik für Frauenheilkunde, Vivantes Klinikum Neuköln, Berlin, Deutschland

    Klaus Vetter

  8. Klinik für Geburtshilfe, Universitätsspital Zürich, USZ, Zürich, Schweiz

    Roland Zimmermann

  9. Pränatale Medizin, Endokrinologie und Osteologie, amedes experts Hamburg Facharzt-Zentrum für Kinderwunsch, Hamburg, Deutschland

    Barbara Sonntag

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Scharf, R., Pestka, M. (2017). Venöse Thromboembolien, Thrombophilie und Thromboseprophylaxe in Gynäkologie und Geburtshilfe. In: Dimpfl, T., et al. Weiterbildung Gynäkologie und Geburtshilfe. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-49480-6_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-49480-6_10

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-49479-0

  • Online ISBN: 978-3-662-49480-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation